- Home
- VINP vs HUMA Comparison
VINP vs HUMA Comparison
Compare VINP & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- HUMA
- Stock Information
- Founded
- VINP 2009
- HUMA 2004
- Country
- VINP Brazil
- HUMA United States
- Employees
- VINP N/A
- HUMA N/A
- Industry
- VINP Investment Managers
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- HUMA Health Care
- Exchange
- VINP Nasdaq
- HUMA Nasdaq
- Market Cap
- VINP 593.2M
- HUMA 367.6M
- IPO Year
- VINP 2021
- HUMA N/A
- Fundamental
- Price
- VINP $9.40
- HUMA $2.47
- Analyst Decision
- VINP Strong Buy
- HUMA Strong Buy
- Analyst Count
- VINP 2
- HUMA 7
- Target Price
- VINP $13.25
- HUMA $13.00
- AVG Volume (30 Days)
- VINP 56.3K
- HUMA 3.4M
- Earning Date
- VINP 08-06-2025
- HUMA 08-12-2025
- Dividend Yield
- VINP 6.92%
- HUMA N/A
- EPS Growth
- VINP N/A
- HUMA N/A
- EPS
- VINP 0.38
- HUMA N/A
- Revenue
- VINP $126,696,258.00
- HUMA $517,000.00
- Revenue This Year
- VINP $70.28
- HUMA N/A
- Revenue Next Year
- VINP $14.37
- HUMA $896.45
- P/E Ratio
- VINP $24.66
- HUMA N/A
- Revenue Growth
- VINP 57.51
- HUMA N/A
- 52 Week Low
- VINP $8.66
- HUMA $1.15
- 52 Week High
- VINP $11.62
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- VINP 43.26
- HUMA 55.25
- Support Level
- VINP $9.20
- HUMA $2.25
- Resistance Level
- VINP $9.94
- HUMA $2.80
- Average True Range (ATR)
- VINP 0.22
- HUMA 0.19
- MACD
- VINP -0.02
- HUMA 0.01
- Stochastic Oscillator
- VINP 27.21
- HUMA 54.55
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.